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(MAP)Abstract Purpose: The purpose of this study was to evaluate laryngeal mask airway placement
conditions achieved with Nalbuphine/Propofol combination when given intravenously as well as
hemodynamic changes if any.
Methods: 60 ASA grade 1 and 11 patients of age group 20–60 years, scheduled for general anesthe-
sia with spontaneous breathing were randomly allocated to receive intravenously either Fentanyl
2 lg/kg, controlled group (Group F, n= 30) or Nalbuphine 0.2 mg/kg (Group N, n= 30), before
induction of anesthesia with Propofol 2–2.5 mg/kg. Heart rate and arterial blood pressure were
measured before induction of anesthesia and at 1, 3, and 5 min after LMA insertion. Assessment
of LMA insertion was done using 6 variables: mouth opening, gagging, swallowing, head and limb
movements, laryngospasm and resistance to insertion. Incidence and duration of apnea were
recorded.
Results: The incidence of coughing/gagging was higher in the F group (50%) compared to the N
group (30%), (P= 0.019). Swallowing was also statistically signiﬁcant (P= 0.017), being higher in
F group (50%), compared to N group (16.6%). Limb moving followed the same pattern being
higher in the F group (40%) compared to (13.3%) in the N group, (P= 0.008). Laryngospasm
was seen in neither group. There was also statistically signiﬁcant difference (P= 0.007) in the inci-
dence of apnea between the control group (F) 86.6% and (N) group. Heart rate variation and MAP
changes were not statistically signiﬁcant in either F or N groups.
Conclusion: The addition of Nalbuphine to Propofol for LMA insertion provides excellent inser-
tion conditions with stable hemodynamics in adults.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
One of the most basic yet crucial skills in modern anesthetic
practice is airway management and failure to secure a patent
airway might end up in catastrophe [1].
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which is non-invasive supra-glottic device with less adverse
cardiovascular response than tracheal tubes simply because
entry through the vocal cords into the larynx is not required
[2,3]. However, deep level of anesthesia is required for safe
and uneventful LMA insertion as coughing, laryngospasm,
and gagging may lead to desaturation, adverse cardiovascular
response and risk of regurgitation and aspiration [4–6].
Propofol has been postulated the induction agent of choice
for LMA placement and this is owing to its depressant action
on upper airway reﬂexes. Nevertheless, Propofol has its down-
side as it has cardiorespiratory depressant action plus purpose-
less patient movement [7]. So, it is not recommended as
standalone drug for LMA insertion and wide range of adju-
vants have been used clinically to obtain best LMA insertion
criteria with negligible side effects [8,9]. The ideal adjuvant
has not been reached yet [10,11]. Nevertheless, opioids have
teamed up with Propofol to reach success rate up to 95%
but apnea, chest tightness, and hypotension are still main
unwanted side effects [12].
Nalbuphine is a potent analgesic. Receptor studies show that
it binds to mu, kappa, and delta receptors, but not to sigma
receptors. Nalbuphine is primarily a kappa agonist/partial mu
antagonist analgesic. Its cardiovascular stability, long duration
of analgesia, no respiratory depression, less nausea and vomit-
ing and potential safety in over dosagemake it an ideal analgesic
to use in children [13,14]. In this research, Nalbuphine/Propofol
combination was investigated for best hemodynamic and laryn-
geal mask airway placement conditions.2. Patients and methods
After approval of the hospital research panel, a total of 60
American Society of Anesthetists (ASA) grade 1 and 11
patients, aged 20–60, enlisted to undergo elective day case sur-
gery under general anesthesia with spontaneous breathing
using a classic laryngeal mask airway (cLMA, the Laryngeal
Mask Company, Glamorgan CF 45, UK) were assigned to
the study. Hernia repair, hydroceles, varicoceles, and orthope-
dic elective surgeries were the most common surgeries, fol-
lowed by biopsies, and postburn plastic ﬂap. Written
informed consent was obtained from each patient. Those with
suspected difﬁcult intubation, known allergy to Fentanyl,
Nalbuphine or Propofol, seizures, neuromuscular disease, car-
diovascular pathology, hepatic or renal disease and long sur-
gery (more than 3 h) were excluded from the study. Patients
received nothing per os 6 h before the surgery and were pre-
medicated with oral midazolam (0.5 mg/kg) in the morning
of the surgery. In the operating table, intravenous access was
established and standard anesthesia monitors were connected
to the patients. The monitored parameters were heart rate
(HR), systolic blood pressure (SBP), diastolic blood pressure
(DBP), mean arterial blood pressure (MAP), respiratory rate
(RR), end tidal CO2 (ET CO2) and oxygen saturation
(SpO2). ECG, ETCO2 and SpO2 were monitored continu-
ously. Recording of these parameters was done at the follow-
ing time intervals: baseline value, immediately before LMA
insertion, one minute after LMA insertion and thereafter
3 min and 5 min. Sealed pre-coded envelopes, were used to
randomly assign patients into 2 groups: group F = Fentanyl
group (n= 30), and group N= Nalbuphine group (n= 30).Fentanyl was given in a dose 2 lg/kg intravenously over
10 s to group F. Nalbuphine in a dose of 0.2 mg/kg was given
as a bolus intravenous dose to group N. Pre-oxygenation was
carried out with 100% oxygen for 5 min. General anesthesia
was induced with Propofol in the dose of 2 mg/kg with
1/2 mL Lidocaine 2% given over 15 s [14], then, we ventilated
the lungs for 60 s with 100% oxygen, immediately followed by
testing loss of corneal reﬂexes and jaw relaxation before
attempting insertion of cLMA.
LMA insertion (size selected on basis body weight) was
done by anesthetist who was unaware of the research method-
ology [15]. In case of cLMAmalposition or malfunction, it was
removed, and a further dose of Propofol (1 mg/kg) was given.
60 s later reinsertion was attempted. Endotracheal intubation
was carried out after 3 unsuccessful trials of cLMA insertion
and lung ventilation.
Once the cLMA was successful, spontaneous breathing was
allowed as the mode of ventilation. If apnea occurred (deﬁned
as absence of respiration for 30 s), ventilation was manually
assisted through cLMA with 100% oxygen to maintain the
arterial oxygen saturation above 95% until regular sponta-
neous respiration resumed. Anesthesia was maintained with
66% air in oxygen and 1–2% Sevoﬂurane.
Our primary outcome was successful insertion of cLMA.
Secondary outcomes were, occurrence of apnea or/and drop
in blood pressure (20% decrease of systolic blood pressure
under baseline value).
Based on six variables on a 3 point scales cLMA insertion
criteria were assessed by two blinded investigators as follows
[16–19]:
1. Resistance to mouth opening: Nil/Slight/Gross
2. Resistance to insertion: Nil/Slight/Gross
3. Swallowing: Nil/Slight/Gross
4. Coughing/gagging: Nil/Slight/Gross
5. Limb/head movements: Nil/Slight/Gross
6. Laryngospasm: Nil/Slight/GrossFor our study purpose occurrence of any of the above vari-
ables that did not require cLMA reposition or reinsertion was
labeled as slight, where gross was the term given to any episode
that leads to cLMA reposition or reinsertion.
2.1. Statistical analysis
Fisher exact test was used to compare dichotomous parame-
ters. Shapiro-Wilk test analyzed the normal distribution of
demographic and procedural data.
A two factor ANOVA using ROC MIXED procedures was
used to analyze repeated measurements of continuous vari-
ables. Data were reported as mean ± SD or median
(interquartile range). A power analysis was initially done,
assuming that LMA placement conditions were continuous
data with normal distribution. In a previous study [16], the
summed score SD of LMA placement conditions intergroup
was 2.5. In order to achieve an intergroup difference of more
than 2, a sample size of 30 patients in each group would be
required. This would create a power of 80% and P value
(P< 0.05%) was accepted as statistically signiﬁcant. LMA
insertion conditions were compared using the Kruskal–Wallis
test, and the Mann–Whitney test was used for multiple inter-
group comparisons.
Table 2 Conditions during LMA placement.
LMA placement conditions F group
(n= 30)
N group
(n= 30)
P
value
Resistance to mouth opening
Nil/Slight/Gross
28/2/0 28/3/0 0.322
Resistance to placement
Nil/Slight/Gross
29/3/0 28/1/1 0.289
Coughing or Gagging
Nil/Slight/Gross
15/13/2 21/8/1 0.019
Swallowing Nil/Slight/Gross 15/14/1 25/5/0 0.017
Movement Nil/Slight/Gross 18/12/0 26/4/0 0.008
Laryngospasm Nil/slight/gross 0/0/0 0/0/0
** Values are number or median.
Table 3 Incidence of apnea.
F group (n= 30) N group (n= 30) P value
Apnea 26 (86.6%) 16 (53.3%) 0.008
** Values are numbers.
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Anesthesia and surgery were uneventful in all patients.
Demographic characteristics including age, weight, height,
male/female ratio and duration of surgery were not signiﬁ-
cantly different (P> 0.05) between F and N groups (Table 1).
Table 2 shows that the incidence of resistance to mouth
opening between the two groups was statistically insigniﬁcant
(P= 0.322). Resistance to cLMA placement was (10%) in
the F group, higher than N group (6.7%); however, this differ-
ence was statistically insigniﬁcant (P= 0.289).
A statistically signiﬁcant difference was detected between
the two groups (P= 0.019) as regards coughing/gagging being
higher in the F group (50%) compared to the N group (30%).
The incidence of swallowing was signiﬁcantly (P= 0.017)
higher in F group (50%), compared to N group (16.6%).
In case of coughing/gagging, further dose of Propofol
1 mg/kg was given to control the incident followed by another
attempt of cLMA insertion 60 s later. No further dose was
needed. Total amount of Propofol was 1485 mg in Fentanyl
group and 1132 mg in Nalbuphine.
Limb moving followed the same pattern being higher in the
F group (40%) compared to (13.3%) the N group. This differ-
ence was statistically signiﬁcant (P= 0.008). Laryngospasm
was not seen in either group.
The total incidence of cLMA reinsertion was higher (13.3%)
in the F group compared to (6.67%) the N group; however, this
difference was not statistically signiﬁcant (P= 0.311).
Table 3 shows statistically signiﬁcant difference (P= 0.008)
in the incidence of apneabetween the twogroups, being 86.6%in
theF group higher than theNgroup, 53.3%.Fig. 1 shows that in
F group, heart rate went higher than baseline values 1 and 3 min
after cLMAplacement, then, gently dropped belowbaseline val-
ues at minute 5. Likewise, heart rate variations in N group
showed similar pattern. However, heart rate variation was not
statistically signiﬁcant in neither F nor N group (P= 0.14).
In the N group, MAP was higher than baseline values,
before cLMA insertion then went up after cLMA placement,
at minute 1 before reaching values lower than baseline ones
at minute 3, and 5. In the F group, there was similar pattern,
although there was slight decrease in MAP just before inser-
tion of cLMA. Nevertheless, this MAP changes were not sta-
tistically signiﬁcant in neither F nor N group (p= 0.62), Fig. 2.
4. Discussion
This study showed that the combination of Nalbuphine and
Propofol improves cLMA insertion compared to Fentanyl–
Propofol.Table 1 Patient characteristics.
Patient characteristics F group
(n= 30)
N group
(n= 30)
P
Age (years) 41 ± 0.44 38 ± 0.36 0.45
Weight (kg) 17.2 16.9 ± 0.36 0.36
Height (cm) 162 ± 0.36 164 ± 0.36 0.11
Gender M/F 18:12 17:13 0.21
Surgery duration (in
min)
76 ± 0.36 81 ± 0.36 0.12
Data are expressed as means ± SD or number (proportion).The following were the cLMA insertion criteria: cough/gag-
ging; swallowing; limb movement; laryngospasm; mouth open-
ing and resistance to insertion.
Cough and gagging were observed more in Fentanyl group
compared to the Nalbuphine group. This higher incidence
could be due to Fentanyl onset of action. We gave 90 s time
between intravenous Fentanyl administration and cLMA
insertion which was not sufﬁcient for full action of Fentanyl
to insert cLMA in a considerable number of patients in this
study. This observation was in accordance with another study
which demonstrated higher dose of Fentanyl was associated
with considerable high incidence of coughing and laryn-
gospasm and attributed these episodes to Fentanyl rather than
to cLMA insertion [20]. Moreover, the antitussive action of
Nalbuphine might have attributed to the low incidence
observed in Nalbuphine compared to Fentanyl group.
Patients in Nalbuphine group showed also less swallowing
and less limb movement than those in Fentanyl group.
Indeed, centrally acting drugs such as Fentanyl and
Nalbuphine would be expected to affect central respiratory
network and consequently may have resulted in a dose related
network change of nasopharyngeal airway reﬂexes [21–23].
Moreover, Nalbuphine mode of action (agonist on K receptors
and antagonist on l receptors, whereas, Fentanyl exerts full
agonist activity on l and k receptors), might directly or indi-
rectly participate in the less incidence of swallowing and limb
movement in the Nalbuphine group. Furthermore, the inci-
dence of apnea was higher in the fentanyl group and this might
alter the reﬂex responses to Fentanyl such as decrease in ven-
tilatory drive resulting in an increase of carbon dioxide.
However, it cannot go without saying that co-administration
of Fentanyl with other anesthetics or administration of higher
doses of Fentanyl may result in different LMA insertion crite-
ria outcomes.
A signiﬁcant difference was also detected between the 2
groups (P= 0.008) as regards higher incidence of apnea in F
group compared to N group. This is to be expected for two
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Figure 1 Changes in heart rate t0, baseline value; t1, one minute prior to LMA placement; t1, t3 and t5 are 1, 3 and 5 min after LMA
placement. Values are mean ± SD or number.
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Figure 2 Changes in mean arterial blood pressure t0, baseline
value; t1, one minute prior to LMA placement; t1, t3 and t5 are 1,
3 and 5 min after LMA placement. Values are mean ± SD or
number.
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[24]; second, Nalbuphine has limited respiratory depression
action owing to its l receptors antagonism. Our results are
in accordance with other studies that investigated upper way
reﬂexes during Fentanyl–Propofol anesthesia [25,12] and
showed high incidence of apnea with Fentanyl. However,
our results show higher incidence of apnea than that reported
by the latter studies, which might be due to the dose of
Fentanyl administered in our study (2 lg/kg) as twice as the
dose used by them 1 lg/kg.
In a placebo controlled [26] study that investigated the
effect of Nalbuphine on heart rate and mean arterial pressure,
it showed signiﬁcant response to intravenous Nalbuphine
administration i.e., more than 20% rise from baseline com-
pared to placebo group. Our study results showed increase in
heart rate and mean arterial blood pressure in both F and N
groups, being higher than baseline values. However, no statis-
tical signiﬁcance could be detected in neither F nor N group
(P= 0.14).
This ﬁnding was in accordance with Khan et al. [27] who
tested Nalbuphine versus Fentanyl on hemodynamics after
intubation, and showed no signiﬁcant alteration in MAP but
HR was signiﬁcantly higher in Nalbuphine group (25%).
Chestnutt et al. [28] also showed smooth hemodynamic
response with intravenous Nalbuphine.
Our study though has got its limitations. First, our research
did not distinguish between central and peripheral apnea inNalbuphine or Fentanyl groups. Second, we cannot exclude
that pre-anesthetic medication (midazolam) might modulate
respiratory reﬂex responses either directly or through interac-
tions with our investigated drugs. However, our rationale
behind using Midazolam is it represents a standard anesthetic
practice.
To conclude, the addition of Nalbuphine to Propofol for
LMA insertion provides excellent insertion conditions with
stable hemodynamics in adults.
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